George Blumenschien

Learn More
OBJECTIVES Preclinical observations that selective cyclooxygenase-2 inhibitors enhance in vitro cell radiosensitivity and in vivo tumor radioresponse led to clinical trials testing therapeutic efficacy of these agents. Our study was designed to determine whether the COX-2 inhibitor celecoxib could be safely administered in doses within those approved by the(More)
This letter is in response to Kiang et al who reported a markedly higher response rate to chemotherapy in estrogen-receptor-positive metastatic breast cancer, as compared to that in receptor-negative tumors. Lippman et al have previously reported opposite findings. Both reports reflect a total lack of uniformity in the type of chemotherapy used for(More)
  • 1